Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol

Stock Information for Cardiol Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiol Therapeutics Inc.

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx(TM) Addressing Patients with Recurrent Pericarditis

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.